This market research report includes a detailed segmentation of the global gastric cancer drugs market by molecule type (small molecules and biologics), by route of administration (oral and parenteral), by lines of chemotherapy (first-line chemotherapy and second-line chemotherapy), and by geography (APAC, Americas, and Europe). The key vendors analyzed in this report are Eli Lilly, F. Hoffmann-La Roche, Sanofi, and Otsuka Holdings.
Technavio has released updated information on the cancer drugs market, with the publication of its new market research report, global gastric cancer drugs market. The global gastric cancer drugs market is expected to grow at a CAGR of 8% between 2016 and 2020. The presence of huge unmet needs in the market has led to increased R&D of safe and effective drugs, thereby boosting the growth of gastric cancer drugs market. APAC is the largest market for gastric cancer drugs. Much of this region’s growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period.
“One of the latest trends emerging in this market is the growing acceptability of gastric cancer drugs, owing to surge in public awareness of gastric cancer treatments. Besides increased dug penetration, this has led to an increase in research funding and support for clinical and support services. Various cancer awareness organizations such as Bowel Cancer Australia and Singapore Cancer Society are spreading awareness about the disease through blogs, Twitter updates, Facebook posts, YouTube videos, and word-of-mouth methods,” says Brahadeesh Chandrasekaran, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
Several off-label chemotherapeutic drugs are used to control gastric cancer proliferation. For instance, Xeloda, capecitabine, epirubicin, cisplatin, fluorouracil, and doxorubicin are some of the chemotherapeutics used to treat gastric cancer. These drugs are also prescribed along with approved drugs as maintenance therapies. In addition, people opt for off-label drugs as they are less expensive than the approved drugs.
The key vendors in the global gastric cancer drugs market include Eli Lilly, F. Hoffmann-La Roche, Sanofi, and Otsuka Holdings. The market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers.
A more detailed analysis is available in the Technavio report, Global Gastric Cancer Drugs Market 2016-2020.
We can customize this reports by other regions and specific segments upon request.
Other related reports:
- Global Colorectal Cancer Drugs Market 2015-2019
- Global Colorectal Cancer Drugs Market 2015-2019
- Global Cancer Pain Therapeutics Market 2015-2019
Further reading:
